Editas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2017 Corporate Update and Results
February 27, 2018 16:01 ET
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., Feb. 27, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Tuesday,...
Editas Medicine Names Jessica Hopfield, Ph.D., to Board of Directors
February 16, 2018 09:00 ET
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., Feb. 16, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced the appointment of Jessica Hopfield, Ph.D., to its Board of...
Editas Medicine to Participate in Upcoming Investor Conferences
February 08, 2018 16:01 ET
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., Feb. 08, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will participate in two upcoming investor...
Editas Medicine Reports on Recent Progress and Announces “EM22” Five-year Goals at J.P. Morgan Healthcare Conference
January 08, 2018 09:00 ET
|
Editas Medicine, Inc.
By the end of 2022, Company expects to have three experimental medicines in early-stage clinical trials and two experimental medicines in or ready for late-stage clinical trials Announces first...
Editas Medicine to Present at the 36th Annual J.P. Morgan Healthcare Conference
January 03, 2018 08:57 ET
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., Jan. 03, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will present a company overview followed by a...
Editas Medicine Reports Data Supporting Multiple Approaches to Create Treatments for Sickle Cell Disease and Beta-Thalassemia
December 11, 2017 18:00 ET
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced results from experiments to demonstrate expanded CRISPR...
Editas Medicine Announces Third Quarter 2017 Results and Update
November 07, 2017 16:03 ET
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., Nov. 07, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today reported financial results for the third quarter ended September 30,...
Editas Medicine to Host Conference Call Discussing Third Quarter 2017 Corporate Update and Results
November 03, 2017 08:00 ET
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., Nov. 03, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Tuesday,...
Editas Medicine to Participate in Investor Conferences in October
October 03, 2017 08:00 ET
|
Editas Medicine
CAMBRIDGE, Mass., Oct. 03, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that management will participate in two upcoming investor...
Editas Medicine Initiates Clinical Natural History Study to Evaluate Patients with Leber Congenital Amaurosis Type 10 (LCA10)
September 12, 2017 08:00 ET
|
Editas Medicine
CAMBRIDGE, Mass., Sept. 12, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that the Company initiated a clinical natural history...